DHR vs MAR: Which Is the Better Buy?
Side-by-side comparison of Danaher Corporation and Marriott International, Inc. — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-07-20.
Danaher Corporation · Healthcare
$195.98
+7.9% upside to fair value
Grade B
High Quality
VS
Marriott International, Inc. · Consumer Cyclical
$366.24
-3.4% upside to fair value
Med Conviction
Grade C
QuantHub Verdict
DHR has more upside to fair value
(+7.9%).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
DHR |
MAR |
| Current Price |
$195.98 |
$366.24 |
| Fair Value Estimate |
$211.54 |
$353.64 |
| Upside to Fair Value |
+7.9%
|
-3.4%
|
| Market Cap |
$138.7B |
$96.6B |
| Forward P/E |
37.8x
|
—
|
| EV / EBITDA |
22.8x
|
23.8x
|
| Price / Sales |
5.6x
|
3.7x
|
| Price / FCF |
26.2x
|
31.6x
|
| Revenue Growth YoY |
+3.7%
|
+6.2%
|
| Gross Margin |
60.7%
|
21.4%
|
| Operating Margin |
21.0%
|
16.0%
|
| Return on Equity |
7.1%
|
-74.1%
|
| Dividend Yield |
0% |
0.75% |
| FCF Yield |
3.81%
|
3.17%
|
| Analyst Consensus |
Strong Buy
|
Hold
|
Investment Thesis
Danaher Corporation operates in the healthcare sector, specifically in medical diagnostics and research, delivering high-quality products with a durable competitive moat supported by strong margins and consistent earnings growth. The company trades at a trailing and forward P/E of 37.76, which is relatively high but justified by its stable revenue growth of 3.7% and earnings growth of 7.9% in the…
Marriott International is a global asset-light hotel franchisor, manager and licensor whose high-quality brands, nearly 283 million Bonvoy members, more than 9,900 properties across 146 countries and record 4,107-property development pipeline create meaningful network, distribution and brand advantages. Q1 2026 demonstrated resilient underlying fee economics: adjusted revenue excluding cost-reimb…
Accumulation Zones
| Metric |
DHR |
MAR |
| Zone Low |
$158.66 |
$265.23 |
| Zone High |
$179.81 |
$300.59 |
| In Buy Zone? |
No
|
No
|